A European Marie Sklodowska-Curie Actions (MSCA) Innovative Training Network (ITN)
PET3D is funded by the European Commission under the H2020 - MSCA-ITN-2015 programme grant agreement No 675417 for a duration of 4 years (June 2016 - May 2020)
"PET3D" - PET Imaging in Drug Design and Development
Drug development is expensive. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and improving the health care system. Positron Emission Tomography (PET) imaging, in particular, is the technology that has the potential to lead this fundamental innovation by providing at a much earlier stage reliable answers to key questions emerging during the care cycle:
what and where is the disease?
Is the disease accurately targeted by the therapy?
Is the treatment effective?
By answering these questions, PET imaging has the capacity to render much more effectively the transition from pre-clinical to clinical phase, and to strongly facilitate the development of better drugs at an earlier stage and in a much more sustainable manner.
The main obstacle to this change of paradigm in drug design and development is the lack of suitably trained translational scientists directly involved in PET imaging and imaging scientists with high-profile training in chemistry and PET-radiochemistry, which is particularly dramatic in Europe. This consortium is ideally suited to provide top-quality training to the next generation of translational PET imaging scientists who will play a key role in shaping the future of drug design and development.
The PET3D ETN will focus on 15 cutting-edge research projects in the 3 main therapeutic areas oncology, cardiovascular, central nervous system.